亚太败血症诊断市场 – 行业趋势和 2029 年预测

请求目录 请求目录 与分析师交谈 与分析师交谈 立即购买 立即购买 购买前请咨询 提前咨询 免费样本报告 免费样本报告

亚太败血症诊断市场 – 行业趋势和 2029 年预测

  • Healthcare
  • Published Report
  • Mar 2022
  • Asia-Pacific
  • 350 页面
  • 桌子數: 56
  • 图号: 28

亚太败血症诊断市场,按技术(微生物学、分子诊断、免疫测定和流式细胞术)、检测类型(实验室检测和即时诊断)划分。行业趋势和预测至 2029 年。

亚太败血症诊断市场

市场分析与洞察:亚太败血症诊断市场  

败血症诊断市场预计将在 2022 年至 2029 年的预测期内实现市场增长。Data Bridge Market Research 分析,在 2022 年至 2029 年的预测期内,该市场将以 8.9% 的复合年增长率增长,预计将从 2021 年的 1.5607 亿美元达到 2029 年的 3.3014 亿美元。医院内感染发病率的上升和败血症患病率的上升推动了预测期内市场的需求。

败血症的历史可以追溯到 2700 多年前,当时它首次在古希腊荷马的诗歌中被提及(医学上)。在他的诗中,他使用了败血症这个词,该词源于希腊语“sepo”,意思是“我腐烂了”。败血症一词也出现在希波克拉底的著作中。他认为败血症是一种可能发生在体内的危险生物腐烂。罗马人进一步发展了败血症理论。败血症最著名的理论之一来自罗马医生盖伦,他的伤口愈合技术持续了 1500 年。他认为败血症是由一种看不见的生物产生的,这些生物会释放出一种叫做“瘴气”的烟雾。

19 世纪,维也纳医生 Ignaz Semmelweiss 对败血症做出了重大发现。他在产房工作时发现,产褥热(又称产褥脓毒症)导致的死亡率很高。后来,他发现一些同事死于手术感染,也就是尸检。Semmelweiss 得出结论,产褥脓毒症与进行尸检的医生之间存在联系。20 世纪 60 年代,美国医生 Edward Frank 制定了第一种脓毒症休克管理策略。1991 年,第一次脓毒症会议召开,旨在解决对脓毒症定义缺乏共识的问题,这种共识给脓毒症的诊断和治疗带来了困难。10 年后,即 2001 年,北美和欧洲的几个协会召开了第二次脓毒症会议,进一步明确了严重脓毒症和脓毒症休克的诊断标准,并制定了管理指南。

The increasing healthcare expenditure is expected to act as driver for the growth of the market. The lack of awareness about sepsis and its symptoms is expected to act as challenge for the growth of the market. The rising technological advancement leading to development of rapid diagnostics tests for early diagnosis of sepsis is expected to act as opportunity for the growth of the market. However, the shortage of healthcare professionals expected to challenge the market growth.

Report Metric

Details

Forecast Period

2022 to 2029

Base Year

2021

Historic Years

2019-2020

Quantitative Units

Revenue in USD Million, Volumes in Units

Segments Covered

By Techniques (Microbiology, Molecular Diagnostic, Immunoassay and Flow Cytometry), Test Type (Laboratory Testing and Point of Care Testing)

Countries Covered

China, India, Japan, South Korea, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Rest of Asia-Pacific

Market Players Covered

Trinity Biotech (Ireland), Meridian Bioscience, Omega Diagnostics Group PLC., Xcyton Diagnostics Limited, Diasorin S.p.A, Seegene Inc., EKF Diagnostics Holdings plc., Axis-Shield Diagnostics Ltd., Immunexpress Inc., Luminex Corporation, bioMérieux SA, BD, Thermo Fisher Scientific Inc. ,Abbott, Roche Diagnostics, Cepheid, Beckman Coulter, Inc., T2 Biosystems, Inc., and Bruker Ortho Clinical Diagnostics

Sepsis Diagnostics Market Dynamics

Drivers

  • Rise in incidence of hospital-acquired infections

The most common hospital-acquired infections (HAIs) are urinary tract infections, pneumonia, and sepsis. The rise in the incidences of hospital-acquired infections (HAIs) will increase the risk of sepsis and hence act as a major driver that will result in the expansion of the growth rate of the treatment market.

  • Rise in healthcare expenditure

Another significant factor influencing the growth rate of sepsis diagnostics market is the rising healthcare expenditure which helps in improving its infrastructure.

  • Grow in prevalence of sepsis

The rise in the prevalence of sepsis will further enhance the growth and hence act as a major driver for sepsis diagnostics market.

Furthermore, rise in technological advancements of sepsis diagnostic devices will expand the sepsis diagnostics market.

Opportunities

  • Development of rapid diagnostic/point of care (POC) techniques for early sepsis diagnosis

Increasing need for the rapid diagnosis of sepsis to reduce the delay of antibiotic therapy among patients with sepsis will boost new opportunities for the market's growth rate.

Also, evolution of novel biomarkers for sepsis diagnosis will provide beneficial opportunities for the sepsis diagnostics market in the forecast period of 2022-2029.

Restraints/Challenges

However, lack of awareness about sepsis and shortage of skilled healthcare professionals will slow down the growth of sepsis diagnostics market. Additionally, high cost of diagnosis and lack of appropriate testing for sepsis will also prove to be harmful for a healthy growth of sepsis diagnostics market in the forecast period mentioned above.

This sepsis diagnostics market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on sepsis diagnostics market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Post COVID-19 Impact on Sepsis Diagnostics Market

The COVID-19 has negatively affected the market. Lockdowns and isolation during pandemics complicate the disease management and medication adherence. The lack of access to health-care facilities for routine diagnosis/blood check-up, consultancy and medication administration will further affect the market. Social isolation increases dismissal of signs and symptoms of sepsis due to fear associated with visiting crowded hospitals and spread of misinformation during the pandemic.

Recent Development

  • In April 2109, Bruker announced the portfolio expansion for Microbial Identification, Infection Control and Molecular Diagnostics of Infectious Diseases. This includes new assays, software and library extensions for its MALDI Biotyper, IR Biotyper and Fluorocycler XT product lines. This has helped company to increase its revenue through new expansions.

亚太败血症诊断市场

Asia-Pacific Sepsis Diagnostics Market Scope

The sepsis diagnostics market is segmented into techniques and test type. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to make strategic decisions to identify core market applications.

Techniques

  • Microbiology
  • Molecular Diagnostic
  • Immunoassay
  • Flow Cytometry

On the basis of techniques, the Asia-Pacific sepsis diagnostics market is segmented into microbiology, molecular diagnostic, immunoassay, and flow cytometry.

Test Type

  • Laboratory Testing
  • Point of Care Testing

On the basis of test type, the Asia-Pacific sepsis diagnostics market is segmented into laboratory testing and point of care testing.

Sepsis Diagnostics Market Regional Analysis/Insights           

The sepsis diagnostics market is analysed and market size insights and trends are provided by country, techniques and test type as referenced above.

The countries covered in the sepsis diagnostics market report are China, India, Japan, South Korea, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, and rest of Asia-Pacific.

China is expected to dominate the Asia-Pacific sepsis diagnostics market due to higher availability of advanced healthcare system and rising number of hospitals, diagnostic centres and clinics which is driving the growth. Asia-Pacific sepsis diagnostics market is expected to grow due to increasing healthcare expenditure by government of developing nations.

The country section of the report also provides individual market impacting factors and changes in regulations in the market that impact the current and future trends of the market. Data points, such as new and replacement sales, country demographics, disease epidemiology, and import-export tariffs, are some of the major pointers used to forecast the market scenario for individual countries. In addition, the presence and availability of Asia-Pacific brands and their challenges faced due to high competition from local and domestic brands, and impact of sales channels are considered while providing forecast analysis of the country data.

Competitive Landscape and Sepsis Diagnostics Market Share Analysis

The sepsis diagnostics market competitive landscape provides details by the competitors. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, Asia-Pacific presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, and application dominance. The above data points provided are only related to the companies' focus on sepsis diagnostics market.

Some of the major players operating in the sepsis diagnostics market are Trinity Biotech (Ireland), Meridian Bioscience, Omega Diagnostics Group PLC., Xcyton Diagnostics Limited, Diasorin S.p.A, Seegene Inc., EKF Diagnostics Holdings plc., Axis-Shield Diagnostics Ltd., Immunexpress Inc., Luminex Corporation, bioMérieux SA, BD, Thermo Fisher Scientific Inc., Abbott, Roche Diagnostics, Cepheid, Beckman Coulter, Inc., T2 Biosystems, Inc., and Bruker Ortho Clinical Diagnostics among others.

Research Methodology: Asia-Pacific Sepsis Diagnostics Market

数据收集和基准年分析是使用具有大样本量的数据收集模块完成的。使用市场统计和连贯模型分析和估计市场数据。此外,市场份额分析和关键趋势分析是市场报告中的主要成功因素。DBMR 研究团队使用的关键研究方法是数据三角测量,其中包括数据挖掘、数据变量对市场影响的分析以及主要(行业专家)验证。除此之外,数据模型还包括供应商定位网格、市场时间线分析、市场概览和指南、公司定位网格、公司市场份额分析、测量标准、亚太地区与地区以及供应商份额分析。如有进一步询问,请要求分析师致电。


SKU-

Get online access to the report on the World's First Market Intelligence Cloud

  • Interactive Data Analysis Dashboard
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
  • Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Request for Demo

目录

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF ASIA PACIFIC SEPSIS DIAGNOSTICS MARKET

1.4 LIMITATIONS

1.5 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 MULTIVARIATE MODELLING

2.7 TECHNIQUES LIFELINE CURVE

2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.9 DBMR MARKET POSITION GRID

2.1 MARKET TECHNIQUES COVERAGE GRID

2.11 VENDOR SHARE ANALYSIS

2.12 SECONDARY SOURCES

2.13 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

5 MARKET OVERVIEW

5.1 DRIVERS

5.1.1 RISE IN INCIDENCE OF HOSPITAL-ACQUIRED INFECTIONS

5.1.2 RISE IN HEALTHCARE EXPENDITURE

5.1.3 GROW IN PREVALENCE OF SEPSIS

5.1.4 RISE IN TECHNOLOGICAL ADVANCEMENTS OF SEPSIS DIAGNOSTIC DEVICES

5.2 RESTRAINTS

5.2.1 HIGH COST OF DIAGNOSIS

5.2.2 LACK OF APPROPRIATE TESTING FOR SEPSIS

5.3 OPPORTUNITIES

5.3.1 DEVELOPMENT OF RAPID DIAGNOSTIC/POINT OF CARE (POC) TECHNIQUES FOR EARLY SEPSIS DIAGNOSIS

5.3.2 EVOLUTION OF NOVEL BIOMARKERS FOR SEPSIS DIAGNOSIS

5.4 CHALLENGES

5.4.1 LACK OF AWARENESS ABOUT SEPSIS

5.4.2 SHORTAGE OF SKILLED HEALTHCARE PROFESSIONALS

6 ASIA PACIFIC SEPSIS DIAGNOSTICS MARKET, BY TECHNIQUES

6.1 OVERVIEW

6.2 IMMUNOASSAY

6.2.1 PROCALCITONIN (PCT)

6.2.2 INTERLEUKIN-6 (IL-6)

6.2.3 C-REACTIVE PROTEIN (CRP)

6.2.4 PENTRAXIN-3 (PTX3)

6.2.5 CALPROTECTIN

6.2.6 OTHERS

6.3 MOLECULAR DIAGNOSTIC

6.4 MICROBIOLOGY

6.5 FLOW CYTOMETRY

7 ASIA PACIFIC SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE

7.1 OVERVIEW

7.2 LABORATORY TESTING

7.3 POINT OF CARE TESTING

8 ASIA PACIFIC SEPSIS DIAGNOSTICS MARKET, BY REGION

8.1 ASIA-PACIFIC

8.1.1 OVERVIEW

8.1.2 CHINA

8.1.3 INDIA

8.1.4 JAPAN

8.1.5 SOUTH KOREA

8.1.6 AUSTRALIA

8.1.7 SINGAPORE

8.1.8 THAILAND

8.1.9 MALAYSIA

8.1.10 INDONESIA

8.1.11 PHILIPPINES

8.1.12 REST OF ASIA-PACIFIC

9 ASIA PACIFIC SEPSIS DIAGNOSTICS MARKET: COMPANY LANDSCAPE

9.1 COMPANY SHARE ANALYSIS: ASIA PACIFIC

10 COMPANY PROFILE

10.1 ROCHE DIAGNOSTICS

10.1.1 COMPANY SNAPSHOT

10.1.2 REVENUE ANALYSIS

10.1.3 COMPANY SHARE ANALYSIS

10.1.4 PRODUCT PORTFOLIO

10.1.5 RECENT DEVELOPMENT

10.2 ABBOTT.

10.2.1 COMPANY SNAPSHOT

10.2.2 REVENUE ANALYSIS

10.2.3 COMPANY SHARE ANALYSIS

10.2.4 PRODUCT PORTFOLIO

10.2.5 RECENT DEVELOPMENT

10.2.5.1 PRODUCT LAUNCH

10.3 BIOMERIEUX SA

10.3.1 COMPANY SNAPSHOT

10.3.2 REVENUE ANALYSIS

10.3.3 COMPANY SHARE ANALYSIS

10.3.4 PRODUCT PORTFOLIO

10.3.5 RECENT DEVELOPMENT

10.3.5.1 PRODUCT LAUNCH

10.4 THERMO FISHER SCINETIFIC INC.

10.4.1 COMPANY SNAPSHOT

10.4.2 REVENUE ANALYSIS

10.4.3 COMPANY SHARE ANALYSIS

10.4.4 PRODUCT PORTFOLIO

10.4.5 RECENT DEVELOPMENT

10.4.5.1 Acquisition

10.5 BD

10.5.1 COMPANY SNAPSHOT

10.5.2 REVENUS ANALYSIS

10.5.3 COMPANY SHARE ANALYSIS

10.5.4 PRODUCT PORTFOLIO

10.5.5 RECENT DEVELOPMENT

10.6 SEEGENE INC.

10.6.1 COMPANY SNAPSHOT

10.6.2 REVENUE ANALYSIS

10.6.3 PRODUCT PORTFOLIO

10.6.4 RECENT DEVELOPMENT

10.7 AXIS-SHIELD DIAGNOSTICS LTD.

10.7.1 COMPANY SNAPSHOT

10.7.2 PRODUCT PORTFOLIO

10.7.3 RECENT DEVELOPMENTS

10.8 BECKMAN COULTER, INC.

10.8.1 COMPANY SNAPSHOT

10.8.2 PRODUCT PORTFOLIO

10.8.3 RECENT DEVELOPMENTS

10.9 BRUKER

10.9.1 COMPANY SNAPSHOT

10.9.2 REVENUS ANALYSIS

10.9.3 PRODUCT PORTFOLIO

10.9.4 RECENT DEVELOPMENTS

10.1 CEPHEID

10.10.1 COMPANY SNAPSHOT

10.10.2 REVENUE ANALYSIS

10.10.3 PRODUCT PORTFOLIO

10.10.4 RECENT DEVELOPMENT

10.10.4.1 Program launch

10.11 DIASORIN S.P.A.

10.11.1 COMPANY SNAPSHOT

10.11.2 REVENUE ANALYSIS

10.11.3 PRODUCT PORTFOLIO

10.11.4 RECENT DEVELOPMENT

10.11.4.1 ACQUISITION

10.12 EKF DIAGNOSTICS HOLDINGS PLC

10.12.1 COMPANY SNAPSHOT

10.12.2 REVENUE ANALYSIS

10.12.3 PRODUCT PORTFOLIO

10.12.4 RECENT DEVELOPMENT

10.12.4.1 Acquisition

10.13 IMMUNEXPRESS INC.

10.13.1 COMPANY SNAPSHOT

10.13.2 PRODUCT PORTFOLIO

10.13.3 RECENT DEVELOPMENT

10.13.3.1 PRODUCT LAUNCH

10.14 LUMINEX CORPORATION.

10.14.1 COMPANY SNAPSHOT

10.14.2 PRODUCT PORTFOLIO

10.14.3 RECENT DEVELOPMENT

10.14.3.1 Acquisition

10.15 MERIDIAN BIOSCIENCE

10.15.1 COMPANY SNAPSHOT

10.15.2 REVENUS ANALYSIS

10.15.3 PRODUCT PORTFOLIO

10.15.4 RECENT DEVELOPMENTS

10.16 OMEGA DIAGNOSTICS GROUP PLC

10.16.1 COMPANY SNAPSHOT

10.16.2 REVENUE ANALYSIS

10.16.3 PRODUCT PORTFOLIO

10.16.4 RECENT DEVELOPMENT

10.17 ORTHO CLINICAL DIAGNOSTICS.

10.17.1 COMPANY SNAPSHOT

10.17.2 REVENUE ANALYSIS

10.17.3 PRODUCT PORTFOLIO

10.17.4 RECENT DEVELOPMENT

10.17.4.1 PRODUCT LAUNCH

10.18 T2 BIOSYSTEM, INC.

10.18.1 COMPANY SNAPSHOT

10.18.2 PRODUCT PORTFOLIO

10.18.3 RECENT DEVELOPMENT

10.18.3.1 PRODUCT LAUNCH

10.19 TRINITY BIOTECH

10.19.1 COMPANY SNAPSHOT

10.19.2 REVENUE ANALYSIS

10.19.3 PRODUCT PORTFOLIO

10.19.4 RECENT DEVELOPMENT

10.2 XCTON DAGNOSTICS LIMITED

10.20.1 COMPANY SNAPSHOT

10.20.2 PRODUCT PORTFOLIO

10.20.3 RECENT DEVELOPMENT

11 QUESTIONNAIRE

12 RELATED REPORTS

表格列表

TABLE 1 ASIA PACIFIC SEPSIS DIAGNOSTICS MARKET, BY TECHNIQUES, 2019-2029 (USD MILLION)

TABLE 2 ASIA PACIFIC IMMUNOASSAY IN SEPSIS DIAGNOSTICS MARKET, BY REGION, 2019-2029 (USD MILLION)

TABLE 3 ASIA PACIFIC IMMUNOASSAY IN SEPSIS DIAGNOSTICS MARKET, BY TECHNIQUES, 2019-2029 (USD MILLION)

TABLE 4 ASIA PACIFIC IMMUNOASSAY IN SEPSIS DIAGNOSTICS MARKET, BY TECHNIQUES, 2019-2029 (UNITS)

TABLE 5 ASIA PACIFIC MOLECULAR DIAGNOSTICS IN SEPSIS DIAGNOSTICS MARKET, BY REGION, 2019-2029 (USD MILLION)

TABLE 6 ASIA PACIFIC MICROBIOLOGY IN SEPSIS DIAGNOSTICS MARKET, BY REGION, 2019-2029 (USD MILLION)

TABLE 7 ASIA PACIFIC FLOW CYTOMETRY IN SEPSIS DIAGNOSTICS MARKET, BY REGION, 2019-2029 (USD MILLION)

TABLE 8 ASIA PACIFIC SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE, 2019-2029 (USD MILLION)

TABLE 9 ASIA PACIFIC LABORATORY TESTING IN SEPSIS DIAGNOSTICS MARKET, BY REGION, 2019-2029 (USD MILLION)

TABLE 10 ASIA PACIFIC POINT OF CARE TESTING IN SEPSIS DIAGNOSTICS MARKET, BY REGION, 2019-2029 (USD MILLION)

TABLE 11 ASIA-PACIFIC SEPSIS DIAGNOSTICS MARKET, BY COUNTRY, 2019-2029 (USD MILLION)

TABLE 12 ASIA-PACIFIC SEPSIS DIAGNOSTICS MARKET, BY TECHNIQUES, 2019-2029 (USD MILLION)

TABLE 13 ASIA-PACIFIC IMMUNOASSAY IN SEPSIS DIAGNOSTICS MARKET, BY TECHNIQUES, 2019-2029 (USD MILLION)

TABLE 14 ASIA-PACIFIC IMMUNOASSAY IN SEPSIS DIAGNOSTICS MARKET, BY TECHNIQUES, 2019-2029 (UNITS)

TABLE 15 ASIA-PACIFIC SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE, 2019-2029 (USD MILLION)

TABLE 16 CHINA SEPSIS DIAGNOSTICS MARKET, BY TECHNIQUES, 2019-2029 (USD MILLION)

TABLE 17 CHINA IMMUNOASSAY IN SEPSIS DIAGNOSTICS MARKET, BY TECHNIQUES, 2019-2029 (USD MILLION)

TABLE 18 CHINA IMMUNOASSAY IN SEPSIS DIAGNOSTICS MARKET, BY TECHNIQUES, 2019-2029 (UNITS)

TABLE 19 CHINA SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE, 2019-2029 (USD MILLION)

TABLE 20 INDIA SEPSIS DIAGNOSTICS MARKET, BY TECHNIQUES, 2019-2029 (USD MILLION)

TABLE 21 INDIA IMMUNOASSAY IN SEPSIS DIAGNOSTICS MARKET, BY TECHNIQUES, 2019-2029 (USD MILLION)

TABLE 22 INDIA IMMUNOASSAY IN SEPSIS DIAGNOSTICS MARKET, BY TECHNIQUES, 2019-2029 (UNITS)

TABLE 23 INDIA SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE, 2019-2029 (USD MILLION)

TABLE 24 JAPAN SEPSIS DIAGNOSTICS MARKET, BY TECHNIQUES, 2019-2029 (USD MILLION)

TABLE 25 JAPAN IMMUNOASSAY IN SEPSIS DIAGNOSTICS MARKET, BY TECHNIQUES, 2019-2029 (USD MILLION)

TABLE 26 JAPAN IMMUNOASSAY IN SEPSIS DIAGNOSTICS MARKET, BY TECHNIQUES, 2019-2029 (UNITS)

TABLE 27 JAPAN SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE, 2019-2029 (USD MILLION)

TABLE 28 SOUTH KOREA SEPSIS DIAGNOSTICS MARKET, BY TECHNIQUES, 2019-2029 (USD MILLION)

TABLE 29 SOUTH KOREA IMMUNOASSAY IN SEPSIS DIAGNOSTICS MARKET, BY TECHNIQUES, 2019-2029 (USD MILLION)

TABLE 30 SOUTH KOREA IMMUNOASSAY IN SEPSIS DIAGNOSTICS MARKET, BY TECHNIQUES, 2019-2029 (UNITS)

TABLE 31 SOUTH KOREA SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE, 2019-2029 (USD MILLION)

TABLE 32 AUSTRALIA SEPSIS DIAGNOSTICS MARKET, BY TECHNIQUES, 2019-2029 (USD MILLION)

TABLE 33 AUSTRALIA IMMUNOASSAY IN SEPSIS DIAGNOSTICS MARKET, BY TECHNIQUES, 2019-2029 (USD MILLION)

TABLE 34 AUSTRALIA IMMUNOASSAY IN SEPSIS DIAGNOSTICS MARKET, BY TECHNIQUES, 2019-2029 (UNITS)

TABLE 35 AUSTRALIA SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE, 2019-2029 (USD MILLION)

TABLE 36 SINGAPORE SEPSIS DIAGNOSTICS MARKET, BY TECHNIQUES, 2019-2029 (USD MILLION)

TABLE 37 SINGAPORE IMMUNOASSAY IN SEPSIS DIAGNOSTICS MARKET, BY TECHNIQUES, 2019-2029 (USD MILLION)

TABLE 38 SINGAPORE IMMUNOASSAY IN SEPSIS DIAGNOSTICS MARKET, BY TECHNIQUES, 2019-2029 (UNITS)

TABLE 39 SINGAPORE SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE, 2019-2029 (USD MILLION)

TABLE 40 THAILAND SEPSIS DIAGNOSTICS MARKET, BY TECHNIQUES, 2019-2029 (USD MILLION)

TABLE 41 THAILAND IMMUNOASSAY IN SEPSIS DIAGNOSTICS MARKET, BY TECHNIQUES, 2019-2029 (USD MILLION)

TABLE 42 THAILAND IMMUNOASSAY IN SEPSIS DIAGNOSTICS MARKET, BY TECHNIQUES, 2019-2029 (UNITS)

TABLE 43 THAILAND SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE, 2019-2029 (USD MILLION)

TABLE 44 MALAYSIA SEPSIS DIAGNOSTICS MARKET, BY TECHNIQUES, 2019-2029 (USD MILLION)

TABLE 45 MALAYSIA IMMUNOASSAY IN SEPSIS DIAGNOSTICS MARKET, BY TECHNIQUES, 2019-2029 (USD MILLION)

TABLE 46 MALAYSIA IMMUNOASSAY IN SEPSIS DIAGNOSTICS MARKET, BY TECHNIQUES, 2019-2029 (UNITS)

TABLE 47 MALAYSIA SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE, 2019-2029 (USD MILLION)

TABLE 48 INDONESIA SEPSIS DIAGNOSTICS MARKET, BY TECHNIQUES, 2019-2029 (USD MILLION)

TABLE 49 INDONESIA IMMUNOASSAY IN SEPSIS DIAGNOSTICS MARKET, BY TECHNIQUES, 2019-2029 (USD MILLION)

TABLE 50 INDONESIA IMMUNOASSAY IN SEPSIS DIAGNOSTICS MARKET, BY TECHNIQUES, 2019-2029 (UNITS)

TABLE 51 INDONESIA SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE, 2019-2029 (USD MILLION)

TABLE 52 PHILIPPINES SEPSIS DIAGNOSTICS MARKET, BY TECHNIQUES, 2019-2029 (USD MILLION)

TABLE 53 PHILIPPINES IMMUNOASSAY IN SEPSIS DIAGNOSTICS MARKET, BY TECHNIQUES, 2019-2029 (USD MILLION)

TABLE 54 PHILIPPINES IMMUNOASSAY IN SEPSIS DIAGNOSTICS MARKET, BY TECHNIQUES, 2019-2029 (UNITS)

TABLE 55 PHILIPPINES SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE, 2019-2029 (USD MILLION)

TABLE 56 REST OF ASIA-PACIFIC SEPSIS DIAGNOSTICS MARKET, BY TECHNIQUES, 2019-2029 (USD MILLION)

图片列表

FIGURE 1 ASIA PACIFIC SEPSIS DIAGNOSTICS MARKET: SEGMENTATION

FIGURE 2 ASIA PACIFIC SEPSIS DIAGNOSTICS MARKET: DATA TRIANGULATION

FIGURE 3 ASIA PACIFIC SEPSIS DIAGNOSTICS MARKET: DROC ANALYSIS

FIGURE 4 ASIA PACIFIC SEPSIS DIAGNOSTICS MARKET: ASIA PACIFIC VS REGIONAL MARKET ANALYSIS

FIGURE 5 ASIA PACIFIC SEPSIS DIAGNOSTICS MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 ASIA PACIFIC SEPSIS DIAGNOSTICS MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 ASIA PACIFIC SEPSIS DIAGNOSTICS MARKET: DBMR MARKET POSITION GRID

FIGURE 8 ASIA PACIFIC SEPSIS DIAGNOSTICS MARKET: MARKET TECHNIQUES COVERAGE GRID

FIGURE 9 ASIA PACIFIC SEPSIS DIAGNOSTICS MARKET: VENDOR SHARE ANALYSIS

FIGURE 10 ASIA PACIFIC SEPSIS DIAGNOSTICS MARKET: SEGMENTATION

FIGURE 11 THE GROWING PREVALENCE OF SEPSIS IS EXPECTED TO DRIVE THE ASIA PACIFIC SEPSIS DIAGNOSTICS MARKET IN THE FORECAST PERIOD OF 2022 TO 2029

FIGURE 12 TECHNIQUES SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA PACIFIC SEPSIS DIAGNOSTICS MARKET IN 2022 & 2029

FIGURE 13 NORTH AMERICA TO DOMINATE AND ASIA-PACIFIC IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE ASIA PACIFIC SEPSIS DIAGNOSTICS MARKET FROM 2022 TO 2029

FIGURE 14 DRIVERS, RESTRAINT, OPPORTUNITIES, AND CHALLENGES FOR THE ASIA PACIFIC SEPSIS DIAGNOSTICS MARKET

FIGURE 15 ASIA PACIFIC SEPSIS DIAGNOSTICS MARKET: BY TECHNIQUES, 2021

FIGURE 16 ASIA PACIFIC SEPSIS DIAGNOSTICS MARKET: BY TECHNIQUES, 2022-2029 (USD MILLION)

FIGURE 17 ASIA PACIFIC SEPSIS DIAGNOSTICS MARKET: BY TECHNIQUES, CAGR (2022-2029)

FIGURE 18 ASIA PACIFIC SEPSIS DIAGNOSTICS MARKET: BY TECHNIQUES, LIFELINE CURVE

FIGURE 19 ASIA PACIFIC SEPSIS DIAGNOSTICS MARKET: BY TEST TYPE, 2021

FIGURE 20 ASIA PACIFIC SEPSIS DIAGNOSTICS MARKET: BY TEST TYPE, 2022-2029 (USD MILLION)

FIGURE 21 ASIA PACIFIC SEPSIS DIAGNOSTICS MARKET: BY TEST TYPE, CAGR (2022-2029)

FIGURE 22 ASIA PACIFIC SEPSIS DIAGNOSTICS MARKET: BY TEST TYPE, LIFELINE CURVE

FIGURE 23 ASIA-PACIFIC SEPSIS DIAGNOSTICS MARKET: SNAPSHOT (2021)

FIGURE 24 ASIA-PACIFIC SEPSIS DIAGNOSTICS MARKET: BY COUNTRY (2021)

FIGURE 25 ASIA-PACIFIC SEPSIS DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2029)

FIGURE 26 ASIA-PACIFIC SEPSIS DIAGNOSTICS MARKET: BY COUNTRY (2021 & 2029)

FIGURE 27 ASIA-PACIFIC SEPSIS DIAGNOSTICS MARKET: BY TECHNIQUES (2022-2029)

FIGURE 28 ASIA PACIFIC SEPSIS DIAGNOSTICS MARKET: COMPANY SHARE 2021 (%)

查看详细信息 Right Arrow

研究方法

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

可定制

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Frequently Asked Questions

The Asia-Pacific Sepsis Diagnostics Market will be projected to grow at a CAGR of 8.9% during the forecast period of 2022 to 2029.
The Asia-Pacific Sepsis Diagnostics Market will be projected USD 330.14 million during the forecast period of 2022 to 2029.
Rise in technological advancements, rise in healthcare expenditure, & rise in the prevalence of sepsis are flourishing the growth of the Asia-Pacific Sepsis Diagnostics Market.
Lack of awareness about sepsis and shortage of skilled healthcare professionals and high cost of diagnosis are poised to restrict the Asia-Pacific Sepsis Diagnostics Market growth.